Iovance Biotherapeutics/$IOVA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Iovance Biotherapeutics
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
- Ticker
- $IOVA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 975
- Headquarters
- Philadelphia, United States
- Website
- www.iovance.com
IOVA Metrics
BasicAdvanced
$3.8B
-
-$0.71
0.76
-
Price and volume
Market cap
$3.8B
Beta
0.76
52-week high
$15.37
52-week low
$1.76
Average daily volume
17M
Financial strength
Current ratio
4.345
Quick ratio
3.742
Long term debt to equity
0.059
Total debt to equity
0.063
Interest coverage (TTM)
-134.50%
Profitability
EBITDA (TTM)
-259.603
Gross margin (TTM)
48.40%
Net profit margin (TTM)
-89.09%
Operating margin (TTM)
-91.14%
Effective tax rate (TTM)
1.45%
Revenue per employee (TTM)
$330,000
Management effectiveness
Return on assets (TTM)
-20.31%
Return on equity (TTM)
-40.36%
Valuation
Price to revenue (TTM)
10.704
Price to book
5.22
Price to tangible book (TTM)
8.14
Price to free cash flow (TTM)
-11.736
Free cash flow yield (TTM)
-8.52%
Free cash flow per share (TTM)
-0.723
Growth
Revenue change (TTM)
34.55%
Earnings per share change (TTM)
-42.71%
3-year revenue growth (CAGR)
1,009.40%
3-year earnings per share growth (CAGR)
-31.56%
10-year earnings per share growth (CAGR)
-0.04%
What the Analysts think about IOVA
Analyst ratings (Buy, Hold, Sell) for Iovance Biotherapeutics stock.
Analyst projections of the future price of Iovance Biotherapeutics stock.
Bulls say / Bears say
Iovance raised its 2026 revenue outlook to $410–420 million, lifting the midpoint by $55 million on sustained demand for Amtagvi and Proleukin. That points to a faster commercial ramp. (Iovance Biotherapeutics)
In a 24-patient Phase 2 study of frontline melanoma, lifileucel plus pembrolizumab produced a 62.5% confirmed response rate and a 29.2% complete response rate. The ongoing Phase 3 trial could test whether this result supports use in a broader patient group. (Nasdaq)
Amtagvi generated about $91 million of Iovance’s $99 million in second-quarter revenue, leaving the company heavily reliant on one product. A slowdown in uptake or access could therefore hit sales hard. (SEC)
Amtagvi requires each patient’s tumour to be collected, expanded into cells and reinfused. This complex process may limit the number of patients and treatment centres able to use it, making commercial growth harder to scale. (CMC Markets)
Iovance remains loss-making and has warned that product revenue may not be enough to produce positive operating cash flow over the next 12 months. It still has launch and clinical development costs to fund. (Iovance Biotherapeutics)
Data summarised monthly by Lightyear AI. Last updated on 29 Oct 2026.
IOVA Financial Performance
Revenues and expenses
IOVA Earnings Performance
Company profitability
Upcoming events
No upcoming events
IOVA News
AllArticlesVideos
Funds containing IOVA
Fund name | Fund size | $IOVA weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.34% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.34% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.34% |
iShares Ageing Population$AGED | $953M | 0.31% |
iShares Ageing Population£AGES | $953M | 0.31% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.